Aa
Gilead’s $84,000 Treatment Questioned by U.S. Lawmakers
Gilead Sciences Inc. (GILD) is being asked by U.S. House Democrats to explain how the company set its $84,000 price for hepatitis C treatment Sovaldi.
The lawmakers also asked Gilead Chief Executive Officer John Martin to explain what is being done to make sure the medicine gets into the hands of low-income patients, especially in government-run health programs.
“Our concern is that a treatment will not cure patients if they cannot afford it,” Democratic representatives Henry Waxman of California, Frank Pallone Jr. of New Jersey, and Diana DeGette of Colorado, wrote in a letter sent yesterday. The lawmakers asked Gilead to brief Congress by April 3.
Gilead’s drug was approved last year as a breakthrough treatment for viral liver infection. The medicine offers higher cure rates and fewer side effects than older treatments, and its high cost has attracted scrutiny and resistance from insurers and public health advocates.
“This letter is a ‘bank shot’ that gets things going, with the goal of getting Gilead to significantly lower the price of Sovaldi,” Terry Haines, a senior political strategist with ISI Group LLC, said in a note to clients. The letter may be a starting point in a campaign to pressure Foster City, California-based Gilead and encourage Republicans and senators of both parties to join the effort, he said.
Gilead declined 4.6 percent to $72.07 at 4 p.m. New York time as the Nasdaq Biotechnology Index of 121 companies fell 4.4 percent.
Lawmakers’ Request
In the letter, the Democrats asked Gilead to explain how the drug was priced, what discounts are being made available to low-income patients and government health programs, and the potential impact to public health by insurers blocking or delaying access to the medicine because of its cost.
The drugmaker said it will meet with Waxman and the other members of Congress.
“We had heard the concerns raised in the letter and had reached out to a number of members of Congress prior to this letter to address those concerns,” Gilead said in a statement. “We have been working with a number of stakeholders, including federal and state officials, to share the scientific and medical evidence.”
Because the Democrats are in the minority in the House of Representatives, the impact of their effort may be minimal, said Justin Simon, an analyst with Height Securities LLC in Washington. “This is unlikely to affect the price of any currently marketed and priced products,” he said.
http://www.bloomberg.com/news/2014-03-21/gilead-s-84-000-treatment-questioned-by-congress.html
The lawmakers also asked Gilead Chief Executive Officer John Martin to explain what is being done to make sure the medicine gets into the hands of low-income patients, especially in government-run health programs.
“Our concern is that a treatment will not cure patients if they cannot afford it,” Democratic representatives Henry Waxman of California, Frank Pallone Jr. of New Jersey, and Diana DeGette of Colorado, wrote in a letter sent yesterday. The lawmakers asked Gilead to brief Congress by April 3.
Gilead’s drug was approved last year as a breakthrough treatment for viral liver infection. The medicine offers higher cure rates and fewer side effects than older treatments, and its high cost has attracted scrutiny and resistance from insurers and public health advocates.
“This letter is a ‘bank shot’ that gets things going, with the goal of getting Gilead to significantly lower the price of Sovaldi,” Terry Haines, a senior political strategist with ISI Group LLC, said in a note to clients. The letter may be a starting point in a campaign to pressure Foster City, California-based Gilead and encourage Republicans and senators of both parties to join the effort, he said.
Gilead declined 4.6 percent to $72.07 at 4 p.m. New York time as the Nasdaq Biotechnology Index of 121 companies fell 4.4 percent.
Lawmakers’ Request
In the letter, the Democrats asked Gilead to explain how the drug was priced, what discounts are being made available to low-income patients and government health programs, and the potential impact to public health by insurers blocking or delaying access to the medicine because of its cost.
The drugmaker said it will meet with Waxman and the other members of Congress.
“We had heard the concerns raised in the letter and had reached out to a number of members of Congress prior to this letter to address those concerns,” Gilead said in a statement. “We have been working with a number of stakeholders, including federal and state officials, to share the scientific and medical evidence.”
Because the Democrats are in the minority in the House of Representatives, the impact of their effort may be minimal, said Justin Simon, an analyst with Height Securities LLC in Washington. “This is unlikely to affect the price of any currently marketed and priced products,” he said.
http://www.bloomberg.com/news/2014-03-21/gilead-s-84-000-treatment-questioned-by-congress.html
Yes, agreed. Thanks for your post.
Left out the word lobbyists and this is the link to the article
about the original bill as proposed:
http://www.nytimes.com/2014/02/22/business/plan-to-alter-medicare-drug-coverage-draws-strong-opposition.html?_r=1
about the original bill as proposed:
http://www.nytimes.com/2014/02/22/business/plan-to-alter-medicare-drug-coverage-draws-strong-opposition.html?_r=1
More options should be available to enable coverage.
On a federal level there was a recent effort to compleely restrict
Medicare coverage to many needed medications
with the justification that there others in the
same class (anti-depressents, antipsychotics
and also some medications for physical conditions).
Ultimately this proposed coverage limit was overturned. However
this had been proposed by the current administration so
the democrats can sometimes be on the wrong side as well.
The influence of corporate undermines medical progress. The cost
of prescriptions is far beyond the funds to research and
develop them, some of which is government funded.
A profit can be made but not at the expense
of people who need the medication to begin with.
On a federal level there was a recent effort to compleely restrict
Medicare coverage to many needed medications
with the justification that there others in the
same class (anti-depressents, antipsychotics
and also some medications for physical conditions).
Ultimately this proposed coverage limit was overturned. However
this had been proposed by the current administration so
the democrats can sometimes be on the wrong side as well.
The influence of corporate undermines medical progress. The cost
of prescriptions is far beyond the funds to research and
develop them, some of which is government funded.
A profit can be made but not at the expense
of people who need the medication to begin with.
You must join this user group in order to participate in this discussion.
You are reading content posted in the Current Events . . . Group
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
